NO20070136L - Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi - Google Patents

Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi

Info

Publication number
NO20070136L
NO20070136L NO20070136A NO20070136A NO20070136L NO 20070136 L NO20070136 L NO 20070136L NO 20070136 A NO20070136 A NO 20070136A NO 20070136 A NO20070136 A NO 20070136A NO 20070136 L NO20070136 L NO 20070136L
Authority
NO
Norway
Prior art keywords
antitumor
potentiating
effect
amount effective
gimeracil
Prior art date
Application number
NO20070136A
Other languages
English (en)
Inventor
Katsuhisa Koizumi
Junji Uchida
Teiji Takechi
Mamoru Nukatsuka
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of NO20070136L publication Critical patent/NO20070136L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Det beskrives et antitumoreffekt-potenserende middel, en fremgangsmåte for behandling av cancer ved anvendelse av en flerhet av farmasøytiske tilberedninger som har utmerket antitumoraktivitet, og et antitumorpreparat. Særlig beskrives et antitumoreffekt-potenserende middel for potensering av antitumoraktiviteten av et antitumorpreparat, omfattende tegafur i en terapeutisk effektiv mengde, gimeracil i en mengde som er effektiv for potensering av en antitumoreffekt, og oteracii-kalium i en mengde som er effektiv for inhibering av en bivirkning, hvor det antitumoreffekt-potenserende middel omfatter cis-oksalat(1R,2R-diaminocykloheksan)platina(II) i en mengde som er effektiv for potensering av antitumoreffekten; en fremgangsmåte for behandling av cancer som omfatter det trinn samtidig å administrere tegafur i en terapeutisk effektiv mengde, gimeracil i en mengde som er effektiv for potensering av en antitumoreffekt, oteracil-kalium i en mengde som er effektiv for inhibering av en bivirkning, og cis-oksalat(1R,2R-diaminocykloheksan)platina(II) i en mengde som er effektiv for potensering av antitumoreffekten; et antitumorpreparat i en farmasøytisk form som omfatter en rekke farmasøytiske midler som hvert inneholder ett av virkestoffene bestående av tegafur, gimeracil, oteracil-kalium og cis-oksalat(1R,2Rdiaminocykloheksan)platina(II) eller som hvert inneholder slike virkestoff i hvilken som helst kombinasjon eller i en farmasøytisk form som omfatter et enkelt farmasøytisk middel som inneholder alle virkestoffene; og et sett.
NO20070136A 2004-06-09 2007-01-08 Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi NO20070136L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004171520 2004-06-09
PCT/JP2005/010182 WO2005120480A1 (ja) 2004-06-09 2005-06-02 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法

Publications (1)

Publication Number Publication Date
NO20070136L true NO20070136L (no) 2007-02-09

Family

ID=35502806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070136A NO20070136L (no) 2004-06-09 2007-01-08 Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi

Country Status (25)

Country Link
US (1) US20080306073A1 (no)
EP (1) EP1757283B1 (no)
JP (1) JP5578753B2 (no)
CN (2) CN1964707A (no)
AU (1) AU2005251588B2 (no)
BR (1) BRPI0511988A (no)
CA (1) CA2569739C (no)
CY (1) CY1113509T1 (no)
DK (1) DK1757283T3 (no)
EA (1) EA011573B1 (no)
ES (1) ES2393398T3 (no)
HR (1) HRP20121062T1 (no)
IL (1) IL179885A (no)
ME (1) ME01460B (no)
MX (1) MXPA06014477A (no)
MY (1) MY140563A (no)
NO (1) NO20070136L (no)
NZ (1) NZ551637A (no)
PL (1) PL1757283T3 (no)
PT (1) PT1757283E (no)
RS (1) RS52668B (no)
SI (1) SI1757283T1 (no)
TW (1) TWI324929B (no)
WO (1) WO2005120480A1 (no)
ZA (1) ZA200700134B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI455732B (zh) * 2007-12-27 2014-10-11 Taiho Pharmaceutical Co Ltd 經口粉粒狀抗腫瘤劑
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
WO2009139085A1 (ja) * 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
CN102309492A (zh) * 2010-07-02 2012-01-11 天津金耀集团有限公司 一种替加氟、吉美斯特和奥替拉西钾复方注射液
EP2826482A4 (en) * 2012-03-16 2015-09-02 Taiho Pharmaceutical Co Ltd NOVEL ANTITUMOR AGENT COMPRISING AN ASSOCIATION OF THREE AGENTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9508554A (pt) * 1994-08-08 1997-11-25 Debiopharm Sa Preparação farmaceuticamente estável de oxaliplatina
AU2001240001A1 (en) * 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
WO2003015521A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations

Also Published As

Publication number Publication date
CA2569739C (en) 2011-11-29
ZA200700134B (en) 2008-05-28
JP5578753B2 (ja) 2014-08-27
DK1757283T3 (da) 2012-11-12
RS52668B (en) 2013-06-28
ES2393398T3 (es) 2012-12-21
AU2005251588B2 (en) 2009-01-08
EP1757283A4 (en) 2009-09-02
CN103054871A (zh) 2013-04-24
TWI324929B (en) 2010-05-21
SI1757283T1 (sl) 2013-01-31
BRPI0511988A (pt) 2008-01-22
JPWO2005120480A1 (ja) 2008-04-03
PT1757283E (pt) 2012-12-07
CN1964707A (zh) 2007-05-16
EA011573B1 (ru) 2009-04-28
EA200602282A1 (ru) 2007-04-27
AU2005251588A1 (en) 2005-12-22
CA2569739A1 (en) 2005-12-22
MXPA06014477A (es) 2007-03-21
HRP20121062T1 (hr) 2013-01-31
CY1113509T1 (el) 2016-06-22
IL179885A (en) 2011-08-31
EP1757283B1 (en) 2012-10-17
IL179885A0 (en) 2007-05-15
ME01460B (me) 2014-04-20
WO2005120480A1 (ja) 2005-12-22
US20080306073A1 (en) 2008-12-11
EP1757283A1 (en) 2007-02-28
MY140563A (en) 2009-12-31
TW200603809A (en) 2006-02-01
PL1757283T3 (pl) 2013-03-29
NZ551637A (en) 2010-05-28

Similar Documents

Publication Publication Date Title
NO20070136L (no) Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi
NO20072654L (no) Cancer behandling
NO20092150L (no) Fremgangsmater for behandling av hyperkolesterolemi
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
MY141119A (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
NO20060381L (no) Humane anti-NGF noytraliserende antistoffer som selektive HGF vei inhibitorer
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
NO20061319L (no) 5-arylpyrimidiner som anticancer legemidler
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2009129531A3 (en) Bupivacaine formulation in a polyorthoester carrier
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
NO20065339L (no) Cholinesteraseinhibitorer i liposomer og deres fremstilling og anvendelse
DK1359939T3 (da) Sammensætning og fremgangsmåde til potensering af lægemidler
WO2011128782A3 (en) Compositions and methods for treating type ii diabetes and related disorders
NO20052954L (no) Diterpenoidforbindelser, sammensetninger derav og deres anvendelse som anti-cancer eller anti-fungale midler
NO20072851L (no) Hoydose forlenget frigivelses formulering av gepiron
TH84859B (th) ตัวเสริมผลต้านเนื้องอก, ส่วนเตรียมต้านเนื้องอก และวิธีสำหรับการรักษามะเร็ง
RU2010150760A (ru) Противоопухолевый агент, набор и способ лечения рака
NO20073942L (no) Farmasoytiske sammensetninger for behandling av sykdommer assosiert med NF-KB-aktivitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application